Does DOSTARLIMAB-GXLY Cause Malignant neoplasm progression? 28 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Malignant neoplasm progression have been filed in association with DOSTARLIMAB-GXLY. This represents 5.6% of all adverse event reports for DOSTARLIMAB-GXLY.
28
Reports of Malignant neoplasm progression with DOSTARLIMAB-GXLY
5.6%
of all DOSTARLIMAB-GXLY reports
4
Deaths
2
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DOSTARLIMAB-GXLY?
Of the 28 reports, 4 (14.3%) resulted in death, 2 (7.1%) required hospitalization, and 1 (3.6%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DOSTARLIMAB-GXLY. However, 28 reports have been filed with the FAERS database.
What Other Side Effects Does DOSTARLIMAB-GXLY Cause?
Off label use (51)
Rash (42)
Death (28)
Fatigue (22)
Neuropathy peripheral (20)
Pyrexia (20)
Product use in unapproved indication (19)
Thrombocytopenia (16)
Hypothyroidism (14)
Erythema (13)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DOSTARLIMAB-GXLY Alternatives Have Lower Malignant neoplasm progression Risk?
DOSTARLIMAB-GXLY vs DOTATATE GALLIUM GA-68
DOSTARLIMAB-GXLY vs DOTHIEPIN
DOSTARLIMAB-GXLY vs DOXAZOSIN
DOSTARLIMAB-GXLY vs DOXAZOSIN\DOXAZOSIN
DOSTARLIMAB-GXLY vs DOXEPIN